# Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer

> **NCT07261592** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 29 (estimated)

## Conditions studied

- Bladder Cancer
- Histone Deacetylase Inhibitor
- Entinostat
- Chemotherapy

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07261592
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07261592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07261592, "Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07261592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*